Home / La Revue Dafee/ High Cholesterol in France
High Cholesterol in France
How common is high cholesterol in France?
Approximately 19 to 27% of French adults have elevated LDL cholesterol, according to the Esteban national health survey by Santé Publique France — making it one of the most common chronic metabolic conditions in the country, comparable in prevalence to hypertension and diabetes.
Using the clinical threshold of LDL above 1.6 g/L: nearly 1 in 5 French adults (19.3%) had elevated LDL cholesterol.
Using the broader definition — elevated LDL or current lipid-lowering treatment — the prevalence rises to 27%.
Source: Santé publique France, Étude Esteban 2015. Bulletin Épidémiologique Hebdomadaire, 2018.
Source: Santé publique France — High cholesterol surveillance, published November 2022.
These figures make high cholesterol one of the most common chronic metabolic conditions in France — comparable in prevalence to hypertension and diabetes.
Who is most affected?
High cholesterol does not affect all groups equally. The Esteban data reveals clear patterns:
By sex: Men have a higher prevalence of elevated LDL than women in absolute terms — 29.8% versus 24.5% using the broader definition. However, this gap narrows significantly after menopause, when estrogen decline removes a key protective mechanism for LDL metabolism. Women aged 55 and above show a marked increase in LDL levels that can equal or exceed those of men in the same age group.
By age: Prevalence increases progressively with age. High cholesterol is relatively rare before 40, rises sharply between 45 and 64, and remains elevated through the 65–74 age range studied.
By treatment status: Among those with elevated LDL in France, only 8.8% were receiving lipid-lowering treatment at the time of the Esteban study. The proportion of adults receiving treatment actually decreased by 29.6% between 2006 and 2015 — a trend that warrants attention given the unchanged prevalence of elevated LDL over the same period.
Source: Santé publique France, Étude Esteban 2015. Bulletin Épidémiologique Hebdomadaire, 2018.
Why do so many people not know they have it?
More than half of French adults with elevated LDL cholesterol — 51.3% — are unaware of their condition, because high LDL produces no symptoms, no pain, and no visible signs. The only way to know is a blood lipid panel.
High LDL cholesterol produces no symptoms. There is no pain, no visible sign, no physical sensation that indicates its presence. It does not cause fatigue, headaches, or any other identifiable subjective experience in the early and middle stages.
The only reliable way to know whether your LDL is elevated is a blood lipid panel — a routine blood test that measures LDL, HDL, total cholesterol, and triglycerides. In France, this test is recommended every five years for adults with no known risk factors, and more frequently for those with family history, hypertension, diabetes, or significant lifestyle risk factors.
The problem is not only getting the test done. It is understanding the result.
A lipid panel produces numbers — LDL 1.82 g/L, HDL 1.1 g/L, total cholesterol 2.6 g/L, triglycerides 1.3 g/L. What these numbers mean in the context of an individual's age, sex, weight, family history, and other risk factors requires interpretation that a standard consultation rarely provides in full.
Source: Santé publique France, Étude Esteban 2015. Cholestérol LDL chez les adultes en France métropolitaine.
What are the consequences of untreated high cholesterol in France?
The population-level consequences of untreated high LDL cholesterol in France are documented and significant.
A nationwide health registry analysis published in the European Heart Journal in 2025 reported that in France, elevated LDL cholesterol levels were attributable to an estimated 230,000 hospital admissions, 1.3 million prevalent cardiovascular disease cases, and 23,000 deaths per year.
Cardiovascular diseases — including coronary heart disease, stroke, and heart failure — remain the leading cause of death in French women and the second leading cause in French men.
High LDL cholesterol is not the only driver of cardiovascular risk, and elevated LDL alone does not determine individual outcomes. Other factors — smoking, hypertension, diabetes, physical inactivity, obesity, family history — interact with lipid levels to shape overall cardiovascular risk. This is why a lipid panel must be interpreted in context, not as a standalone number.
Source: European Heart Journal — Cardiovascular prevention 2024, lipid disorders. Published 2025. DOI: 10.1093/eurheartj/ehaf463
Source: IHME Global Health Data Exchange — France cardiovascular disease burden, 2021.
What does this mean for your lipid panel?
If you have had a blood test in France in the past five years, your lipid panel results are part of your medical record. Whether you received a full explanation of those results — what each number means, what your overall pattern indicates, how your profile compares to population norms — is another question.
The Esteban data shows that more than half of French adults with elevated LDL do not know they have it. This is not because they have not been tested. It is because the gap between receiving a result and understanding what it means remains wide.
A lipid panel is not a verdict. It is a piece of information. What matters is what you do with it.
The Dafee Metabolic Intelligence app interprets your lipid panel — LDL, HDL, total cholesterol, triglycerides, and their ratios — in plain language. It does not diagnose. It translates. It gives you the context your result needs to be meaningful.
Free. No registration required. Three minutes.
Written by the Dafee Science Team — published 15/06/2026. Dafeepédia content is developed from European regulatory sources (EFSA, EC Regulation 432/2012) and peer-reviewed scientific literature, and reviewed for accuracy before publication.
The Dafee Metabolic Intelligence app interprets standard lipid blood panels as metabolic patterns rather than isolated thresholds — available at app.dafee.fr.